{"entity":{"id":"cobas-ezh2-mutation-test","kind":"drug","name":"cobas EZH2 Mutation Test","aka":[],"tldr":"The Roche test that found an EZH2 mutation in follicular lymphoma to select tazemetostat. Tazemetostat has since been withdrawn, and the FDA records the test's own approval as withdrawn on 6 July 2026.","summary":"Roche Molecular Systems' cobas EZH2 Mutation Test was approved on 18 June 2020 (PMA P200014) to identify people with follicular lymphoma whose tumour carries an EZH2 mutation, for treatment with tazemetostat (Tazverik). The FDA's PMA page for the test gives a withdrawal date of 6 July 2026, and openFDA's copy of the same database gives the original approval the decision code APWD, which its field definitions define as withdrawal after approval. The FDA companion diagnostic list, last updated on 3 November 2026, still printed the test. Tazemetostat itself was withdrawn in 2026 (see its page).","status":"withdrawn","asOf":"2026-11-19","links":[{"label":"openFDA PMA record P200014 (original approval)","url":"https://api.fda.gov/device/pma.json?search=pma_number:P200014+AND+supplement_number:%22%22"},{"label":"openFDA: PMA field definitions, including decision codes","url":"https://open.fda.gov/fields/devicepma.yaml"},{"label":"FDA PMA P200014","url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200014"},{"label":"FDA: List of FDA-Authorized Companion Diagnostic Devices","url":"https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-fda-authorized-companion-diagnostic-devices-in-vitro-and-imaging-tools"}],"tags":["test"],"related":[],"cancers":["follicular-lymphoma"],"sections":[],"technologies":["companion-diagnostic"],"targets":["ezh2"],"drugs":["tazemetostat"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":["pcr","companion-diagnostic-term"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The FDA PMA page for P200014 reads Withdrawal Date 07/06/2026 and the openFDA entry for the original approval reads decision_code APWD, both read 19 November 2026. openFDA also lists 30-day manufacturing notices for the same PMA, the latest dated 27 October 2026, after the withdrawal date; notices with the same dates and wording sit on the cobas KRAS test (P140023), and the FDA page does not explain them."],"brand":"cobas EZH2 Mutation Test","modality":"Real-time allele-specific PCR companion diagnostic test (EZH2 mutations, follicular lymphoma tissue)","mechanism":"Real-time allele-specific PCR for the EZH2 single-nucleotide mutations Y646N, Y646F, Y646X (Y646H, Y646S or Y646C), A682G and A692V in DNA from formalin-fixed, paraffin-embedded follicular lymphoma tissue.","approvals":[{"region":"US","year":2020,"indication":"Companion diagnostic for tazemetostat in EZH2-mutant follicular lymphoma","note":"Approval withdrawn on 6 July 2026 (FDA PMA page, withdrawal date; openFDA decision code APWD)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cobas-ezh2-mutation-test/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"technology":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/"}],"target":[{"id":"ezh2","kind":"target","name":"EZH2","route":"/targets/ezh2/"}],"drug":[{"id":"tazemetostat","kind":"drug","name":"Tazemetostat","route":"/drugs/tazemetostat/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"term":[{"id":"companion-diagnostic-term","kind":"term","name":"Companion diagnostic","route":"/terms/companion-diagnostic-term/"},{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/"}]}}